Silexion Therapeutics Corp (SLXN)

NASDAQ: SLXN · Real-Time Price · USD

9.28

-5.66 (-37.88%)

At close: Aug 1, 2025, 4:00 PM

9.45

+0.17 (1.83%)

After-hours: Aug 1, 2025, 4:51 PM EDT

Silexion Therapeutics Employees

As of December 31, 2024, Silexion Therapeutics had 14 total employees, including 11 full-time and 3 part-time employees.

Employees

14

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$1,174,500

Market Cap

5.21M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	14	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

SLXN News

21 hours ago - Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds - GlobeNewsWire
1 day ago - Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation - GlobeNewsWire
16 days ago - Silexion Therapeutics Announces 1-for-15 Reverse Share Split - GlobeNewsWire
23 days ago - Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines - GlobeNewsWire
2 months ago - PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment - GlobeNewsWire
2 months ago - Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer - GlobeNewsWire
2 months ago - Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
3 months ago - Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities - GlobeNewsWire